Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 35 of the 36 references it cites were found in a registry or an index.

Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: results from a Phase 2 trial

Open access

Abstract

Background: Fosmanogepix is a first-in-class antifungal targeting the fungal enzyme Gwt1, with broad-spectrum activity against yeasts and moulds, including multidrug-resistant fungi, formulated for intravenous (IV) and oral administration. Methods: This global, multicenter, non-comparative study evaluated the safety and efficacy of fosmanogepix for first-line treatment of candidaemia in non-neutropenic adults. Participants with candidaemia, defined as a positive blood culture for Candida spp. within 96 h prior to study entry, with ≤2 days of prior systemic antifungals, were eligible. Participants received fosmanogepix for 14 days: 1000 mg IV twice daily on Day 1, followed by maintenance 600 mg IV once daily, and optional switch to 700 mg orally once daily from Day 4. Eligible participants who received at least one dose of fosmanogepix and had confirmed diagnosis of candidaemia (<96 h of treatment start) composed the modified intent-to-treat (mITT) population. Primary efficacy endpoint was treatment success at the end of study treatment (EOST) as determined by the Data Review Committee. Success was defined as clearance of Candida from blood cultures with no additional antifungal treatment and survival at the EOST. Results: Treatment success was 80% (16/20, mITT; EOST) and Day 30 survival was 85% (17/20; 3 deaths unrelated to fosmanogepix). Ten of 21 (48%) were switched to oral fosmanogepix. Fosmanogepix was well tolerated with no treatment-related serious adverse events/discontinuations. Fosmanogepix had potent in vitro activity against baseline isolates of Candida spp. (MICrange: CLSI, 0.002–0.03 mg/L). Conclusions: Results from this single-arm Phase 2 trial suggest that fosmanogepix may be a safe, well-tolerated, and efficacious treatment for non-neutropenic patients with candidaemia, including those with renal impairment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jac/dkad256

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Study schematic. Time period (<96 h) to complete eligibility assessments started at the time that the sample for the blood culture positive for Candida was collected. EOST may be the same as EOT for those participants who do not step-down to fluconazole or alternative antifungal therapy. EOST, end of study treatment; EOT, end of treatment; FMGX, fosmanogepix; IV, intravenous; PO, oral.
Figure 1. Study schematic. Time period (<96 h) to complete eligibility assessments started at the time that the sample for the blood culture positive for Candida was collected. EOST may be the same as EOT for those participants who do not step-down to fluconazole or alternative antifungal therapy. EOST, end of study treatment; EOT, end of treatment; FMGX, fosmanogepix; IV, intravenous; PO, oral.CC BY-NC · PubMed Central
Figure 2. Participant disposition. AE, adverse event; FMGX, fosmanogepix; ITT, intent-to-treat; mITT, modified intent-to-treat.
Figure 2. Participant disposition. AE, adverse event; FMGX, fosmanogepix; ITT, intent-to-treat; mITT, modified intent-to-treat.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Research works printed but not linked: 1

  1. CLSI, 2017, Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts—Fourth Edition: M27

Cited by

See all 70

Metadata

Authors
Pappas, P. G., Vazquez, J. A., Oren, I., Rahav, G., Aoun, M., Bulpa, P., Ben-Ami, R., Ferrer, R., Mccarty, T., Thompson, G. R., Schlamm, H., Bien, P. A., Barbat, S. H., Wedel, P., Oborska, I., Tawadrous, M., & Hodges, M. R.
Affiliations
  • University of Alabama at Birmingham (US)
  • Division of Infectious Disease, Department of Medicine, Medical College of Georgia/Augusta University , Augusta, GA , USA
  • Rambam Health Care Campus (IL)
  • Tel Aviv University (IL)
  • Department of Internal Medicine, Institut Jules Bordet , Brussels , Belgium
  • CHU Dinant Godinne UCL Namur (BE)
  • Chaim Sheba Medical Center, Sackler School of Medicine, Tel Aviv University , Tel Aviv , Israel
  • Vall d'Hebron Institut de Recerca (ES)
  • University of California Davis Medical Center (US)
  • Amplyx Pharmaceuticals (United States) (US)
  • Pfizer (United States) (US)
Corresponding author
Tawadrous, Margaret
Venue
Journal of Antimicrobial Chemotherapy
Published
2023-08-19
Volume
78
Issue
10
Pages
2471-2480
ISSN
  • 0305-7453 (ISSN-L)
  • 1460-2091
OpenAlex
W4386002220
Cited by
65
References
36
Citations by year
2026: 19 · 2025: 19 · 2024: 25 · 2023: 2
FWCI
13.45
Type
journal article
Language
en
Open access
Locations
  • Journal of Antimicrobial Chemotherapy (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by-nc)
  • Digital Access to Libraries (submittedVersion, other-oa)
  • Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, other-oa)
Funders
  • Amplyx
  • Pfizer Inc
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
  • Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
Keywords
fosmanogepix, candidemia, Candida, antifungal agents, non-neutropenic patients, treatment success, survival, renal dysfunction, multidrug-resistant fungi, safety and tolerability
MeSH terms
Adult, Antifungal Agents, Candida, Fungi, Humans, Treatment Outcome, Candidemia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: results from a Phase 2 trial. https://app.cochat.ai/papers/10.1093/jac/dkad256
The paper
Pappas, P. G., Vazquez, J. A., Oren, I., Rahav, G., Aoun, M., Bulpa, P., Ben-Ami, R., Ferrer, R., Mccarty, T., Thompson, G. R., Schlamm, H., Bien, P. A., Barbat, S. H., Wedel, P., Oborska, I., Tawadrous, M., & Hodges, M. R. (2023). Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: results from a Phase 2 trial. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkad256

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.